Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

US7572794B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Rolf Bohlmann · Berlin, DE
• Martin Haberey · Berlin, DE
• Andreas Huth · Berlin, DE
• Stuart Ince · Berlin, DE
• Martin Krueger · Berlin, DE
• Karl-Heinz Thierauch · Berlin, DE
• Holger Hess-Stumpp · Berlin, DE

Key dates

• Filing date: Nov 3, 2005
• Grant date: Aug 11, 2009
• Expiry date: May 23, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.